Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Clobetasol propionate nanoparticle - China Grand Pharmaceutical/Formosa Pharmaceuticals

Next Previous
Drug Profile

Clobetasol propionate nanoparticle - China Grand Pharmaceutical/Formosa Pharmaceuticals

Alternative Names: APP-13007; BYQLOVI; EYEN-530; GPN-00833

Latest Information Update: 16 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Activus Pharma; Sosei Heptares
  • Developer Formosa Pharmaceuticals; Grand Pharmaceutical Group
  • Class Analgesics; Anti-inflammatories; Antipsoriatics; Antiulcers; Corticosteroids; Eye disorder therapies; Fluorinated steroids; Glucocorticoids; Halogenated hydrocarbons; Propionates
  • Mechanism of Action Steroid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Ocular inflammation; Ocular pain

Most Recent Events

  • 09 Jun 2025 Formosa Pharmaceuticals and Harrow enters into a licensing agreement for Clobetasol Propionate Ophthalmic Suspension for the treatment of Ocular Inflammation and Pain
  • 28 May 2025 Formosa Pharmaceuticals and Adalvo Limited enters into a licensing agreement for Clobetasol Propionate Ophthalmic Suspension for the treatment of Ocular Inflammation and Pain
  • 06 May 2025 Clobetasol propionate nanoparticle licensed to Apotex for Ocular inflammation and Ocular pain in Mexico

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top